Long-acting reversible contraception (LARC) with the intrauterine system with levonorgestrel (6âmcg/d): observational study on the acceptability, quality of life, and sexuality in Italian women
Neri, Manuela;Paoletti, Anna Maria;Vallerino, Valerio;Corda, Valentina;Ronchetti, Camilla;Taccori, Valeria;Melis, Gian Benedetto;Mais, Valerio
2018-01-01
Abstract
This observational study was conducted in healthy premenopausal women, who presented themselves for contraception with an intrauterine system (IUS) releasing LNG (6âmcg/d) (Jaydess®, Bayer, Germany) at the outpatient Family Planning Clinics of the Departments of Obstetrics and Gynaecology of the Universities of Cagliari and Sassari (CA/SS), University-Hospitals of CA/SS (Italy). After a screening visit, 31 women without contraindications to Jaydess® were included in the study. No difficulty in Jaydess® insertion (Ji) was found in 87% of subjects, with pelvic pain (PP) (visual analogic scale, VAS:5.33â±â2.54) reported by 27/31 subjects at the Ji. Pelvic pain was reported by 17/31 subjects on the first day (VAS: 3.07â±â3.1), 16/31 subjects on the second day (VAS:2.37â±â2.71), and 11/31 subjects on the third day (VAS:1.18â±â2.02) from Ji, with a significant (pâ <â.001) decrease in the intensity. the primary purposes of study were to evaluate whether a 12-month-treatment (12-m-t) with jaydessâ® interferes on either quality life (qol) or sexuality. did not modify qol sexuality 25 subjects who completed 12-m-t. throughout 12-m-t, pp, pregnancies found; menstrual blood loss was significantly (pâ<â.0001) reduced, and intensity vas dysmenorrhea (#14 subjects) (pâ<â.001) improved. < div>File | Size | Format | |
---|---|---|---|
Neri M et al, Jaydess Gynecological Endocrinology.pdf Solo gestori archivio
Description: articolo principale
Type: versione editoriale
Size 693.58 kB
Format Adobe PDF
|
693.58 kB | Adobe PDF | & nbsp; View / Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.